These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36653728)

  • 41. Unwarranted, long term, alglucosidase alfa enzyme replacement therapy in two non-Pompe disease patients.
    Karam C; Ragole T; Moshe-Lilie O; Chahin N
    Clin Neurol Neurosurg; 2020 Sep; 196():106048. PubMed ID: 32623214
    [No Abstract]   [Full Text] [Related]  

  • 42. Toward deconstructing the phenotype of late-onset Pompe disease.
    Schüller A; Wenninger S; Strigl-Pill N; Schoser B
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):80-8. PubMed ID: 22253010
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Alglucosidase alfa: new drug. Pompe disease: a short-term benefit.
    Prescrire Int; 2007 Dec; 16(92):240-1. PubMed ID: 18092404
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: a multicentre observational cohort study from the European Pompe Consortium.
    Ditters IAM; Huidekoper HH; Kruijshaar ME; Rizopoulos D; Hahn A; Mongini TE; Labarthe F; Tardieu M; Chabrol B; Brassier A; Parini R; Parenti G; van der Beek NAME; van der Ploeg AT; van den Hout JMP;
    Lancet Child Adolesc Health; 2022 Jan; 6(1):28-37. PubMed ID: 34822769
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Investigation on acute effects of enzyme replacement therapy and influence of clinical severity on physiological variables related to exercise tolerance in patients with late onset Pompe disease.
    Sechi A; Salvadego D; Da Ponte A; Bertin N; Dardis A; Cattarossi S; Devigili G; Reccardini F; Bembi B; Grassi B
    Neuromuscul Disord; 2017 Jun; 27(6):542-549. PubMed ID: 28433478
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Newborn screening for Pompe disease: Parental experiences and follow-up care for a late-onset diagnosis.
    Prakash S; Penn JD; Jackson KE; Dean LW
    J Genet Couns; 2022 Dec; 31(6):1404-1420. PubMed ID: 35915971
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment.
    Montagnese F; Barca E; Musumeci O; Mondello S; Migliorato A; Ciranni A; Rodolico C; De Filippi P; Danesino C; Toscano A
    J Neurol; 2015; 262(4):968-78. PubMed ID: 25673129
    [TBL] [Abstract][Full Text] [Related]  

  • 48. FDA approves new treatment for late-onset Pompe disease.
    Home Healthc Nurse; 2010 Sep; 28(8):457. PubMed ID: 20811179
    [No Abstract]   [Full Text] [Related]  

  • 49. Selective screening of late-onset Pompe disease (LOPD) in patients with non-diagnostic muscle biopsies.
    Meznaric M; Fumic K; Leonardis L
    J Clin Pathol; 2019 Jul; 72(7):468-472. PubMed ID: 30878973
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Expert Group Consensus on early diagnosis and management of infantile-onset pompe disease in the Gulf Region.
    Al-Hassnan Z; Hashmi NA; Makhseed N; Omran TB; Al Jasmi F; Teneiji AA
    Orphanet J Rare Dis; 2022 Oct; 17(1):388. PubMed ID: 36303251
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients.
    Masat E; Laforêt P; De Antonio M; Corre G; Perniconi B; Taouagh N; Mariampillai K; Amelin D; Mauhin W; Hogrel JY; Caillaud C; Ronzitti G; Puzzo F; Kuranda K; Colella P; Mallone R; Benveniste O; Mingozzi F;
    Sci Rep; 2016 Nov; 6():36182. PubMed ID: 27812025
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Qualitative interviews to improve patient-reported outcome measures in late-onset Pompe disease: the patient perspective.
    Hamed A; An Haack K; Gwaltney C; Baranowski E; Stewart A; Krupnick R; Tyler M; Sparks S; Paty J
    Orphanet J Rare Dis; 2021 Oct; 16(1):428. PubMed ID: 34641935
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Baseline Urinary Glucose Tetrasaccharide Concentrations in Patients with Infantile- and Late-Onset Pompe Disease Identified by Newborn Screening.
    Chien YH; Goldstein JL; Hwu WL; Smith PB; Lee NC; Chiang SC; Tolun AA; Zhang H; Vaisnins AE; Millington DS; Kishnani PS; Young SP
    JIMD Rep; 2015; 19():67-73. PubMed ID: 25681082
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intracranial arterial abnormalities in patients with late onset Pompe disease (LOPD).
    Montagnese F; Granata F; Musumeci O; Rodolico C; Mondello S; Barca E; Cucinotta M; Ciranni A; Longo M; Toscano A
    J Inherit Metab Dis; 2016 May; 39(3):391-398. PubMed ID: 26830551
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phenotypic implications of pathogenic variant types in Pompe disease.
    Viamonte MA; Filipp SL; Zaidi Z; Gurka MJ; Byrne BJ; Kang PB
    J Hum Genet; 2021 Nov; 66(11):1089-1099. PubMed ID: 33972680
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Are there common walking gait characteristics in patients diagnosed with late-onset Pompe disease?
    Starbuck C; Reay J; Silk E; Roberts M; Hendriksz C; Jones R
    Hum Mov Sci; 2021 Jun; 77():102777. PubMed ID: 33730657
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Enzyme replacement therapy with alglucosidase alfa in Pompe disease: Clinical experience with rate escalation.
    Desai AK; Walters CK; Cope HL; Kazi ZB; DeArmey SM; Kishnani PS
    Mol Genet Metab; 2018 Feb; 123(2):92-96. PubMed ID: 29289479
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical efficacy of the enzyme replacement therapy in patients with late-onset Pompe disease: a systematic review and a meta-analysis.
    Sarah B; Giovanna B; Emanuela K; Nadi N; Josè V; Alberto P
    J Neurol; 2022 Feb; 269(2):733-741. PubMed ID: 33851281
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pompe disease: An Indian series diagnosed on muscle biopsy by ultrastructural characterization.
    Kakkar A; Sharma MC; Nambirajan A; Gulati S; Bhatia R; Suri V; Sarkar C
    Ultrastruct Pathol; 2018; 42(3):211-219. PubMed ID: 29565761
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Decreased outlet angle of the superior cerebellar artery as indicator for dolichoectasia in late onset Pompe disease.
    Hensel O; Schneider I; Wieprecht M; Kraya T; Zierz S
    Orphanet J Rare Dis; 2018 Apr; 13(1):57. PubMed ID: 29653542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.